FindTrial
Sign In

Anti-SEMA4D Monoclonal Antibody VX15/2503

BIOLOGICAL2 trials

Sponsors

Emory University, Jonsson Comprehensive Cancer Center

Conditions

Colon Carcinoma Metastatic in the LiverColorectal AdenocarcinomaMetastatic MelanomaPancreatic AdenocarcinomaResectable Pancreatic CarcinomaStage I Pancreatic CancerStage IA Pancreatic CancerStage IB Pancreatic Cancer

Phase 1

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
CompletedNCT03373188
Emory UniversityColon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma +11
Start: 2017-12-15End: 2021-10-28Updated: 2024-03-20
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
TerminatedNCT03425461
Jonsson Comprehensive Cancer CenterMetastatic Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7 +3
Start: 2018-06-14End: 2021-03-04Updated: 2021-04-02

Related Papers

Abstract A15: Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors
Clinical Cancer Research2020-06-15
Abstract CT016: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors
Cancer Research2019-07-012 citations
Abstract 1545: Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies
Cancer Research2019-07-01
Abstract 1545: Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies
Immunology2019-07-01
Abstract CT016: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors
Clinical Trials2019-07-01
Abstract PR10: Reprogramming myeloid cells in TME with pepinemab, first-in-class semaphorin 4D MAb, enhances combination immunotherapy
Cancer Immunology Research2019-02-01